Made available in DSpace on 2014-06-11T19:22:58Z (GMT). No. of bitstreams: 0 Previous issue date: 2011-02-17Bitstream added on 2014-06-13T18:08:59Z : No. of bitstreams: 1 ishii_pl_me_rcla.pdf: 341469 bytes, checksum: 30957c71a427ca667e0c86edb9d40228 (MD5) / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / A Nutrigenômica é definida como o efeito da dieta na expressão gênica, e a extensão pela qual as diferenças genéticas entre os indivíduos influenciam a resposta a um padrão específico de dieta, à ingestão de alimentos funcionais e à suplementação de micronutrientes, em termos de um resultado para a saúde humana. A α-tomatina é um glicoalcalóide encontrado no tomate (Lycopersicon esculentum) que possui funções biológicas importantes como a redução dos níveis de colesterol LDL, inibição do crescimento de células cancerosas, estimulação do sistema imune e efeito antimetastático. O objetivo deste estudo foi avaliar a citotoxicidade da α-tomatina, os seus efeitos na proliferação celular, na indução de apoptose e expressão de RNAm dos genes APC, Ciclina A2, Catenina, CASP9, BAK, BAX e BCL-XL em células HT29. As células foram cultivadas em meio de cultura DMEM, suplementado com 10% de soro bovino fetal, e tratadas nas concentrações de 0,1, 1 e 10 μg/mL para o ensaio do MTT e proliferação celular. Na análise de apoptose morfológica utilizou-se as concentrações de 0,1, 1 e 2 μg/mL. Já para a avaliação da expressão gênica utilizou-se a concentração de 1 μg/mL. Após 12 horas de tratamento, o RNA das células foi extraído e a expressão dos genes foi avaliada através do método de PCR em tempo real. O gene GPDH foi utilizado como normalizador. A análise estatística foi realizada por ANOVA/Tukey para o ensaio do MTT. Os resultados do ensaio de cinética de proliferação celular, viabilidade celular e avaliação da indução de apoptose foram analisados estatisticamente através de ANOVA/Dunnet, e para a análise da expressão gênica utilizou-se o método de Pfaffl et al. (2002), através do cálculo estimado pelo método ΔΔCt. Os estudos experimentais indicaram que a α-tomatina foi citotóxica apenas na concentração de 10 μg/mL... / Nutrigenomics is defined as the effect of diet on gene expression, and the extent to which genetic differences between individuals influence the response to a specific pattern of diet, intake of functional foods and micronutrient supplementation, in terms of a result for human health. The α- tomatine is highlighted as a glycoalkaloid found in tomato (Lycopersicon esculentum) that has important biological functions such as reducing levels of LDL cholesterol, inhibit cancer cell growth, stimulation of the immune system and antimetastátic effect. In view of these considerations, the objective of this study was to evaluate the cytotoxicity of α-tomatine, their effects on cell proliferation, induction of apoptosis and morphological expression of mRNA of APC gene, Cyclin A2, β-Catenin, CASP9, BAK, BAX and BCL-XL in HT29 cells. The cells were grown in DMEM culture medium supplemented with 10% fetal bovine serum, and treated at concentrations of 0.1, 1 and 10μg/mL for the MTT assay and cell proliferation. In the morphological analysis of apoptosis, we used concentrations of 0.1, 1 and 2μg/mL. As for the evaluation of gene expression we used a concentration of 1 mg/mL. After 12 hours of treatment, the RNA from cells was extracted and gene expression was evaluated by the method of real-time PCR. The gene GPDH was used as normalizer. Statistical analysis was performed by ANOVA / Tukey test for MTT. The test results of kinetics of cell proliferation, cell viability and assessment of apoptosis were analyzed with ANOVA / Dunnet, and for analysis of gene expression we used the method of Pfaffl et al. (2002), by calculating estimated by ΔΔCt. Experimental studies suggested that α-tomatine was cytotoxic only at concentration of 10μg/mL. In the evaluation of cell proliferation were no significant differences in the treatments with α-tomatine, except that for the concentration... (Complete abstract click electronic access below)

Quinases dependentes de ciclinas (CDKs) compreendem uma família de proteínas que podem ser subdivididas em dois grupos funcionais majoritários baseados na sua função no ciclo celular e/ou controle transcricional. Já foram identificadas mais de 30 CDKs humanas. A CDK10 é uma proteína quinase dependente de ciclina pertencente ao grupo de quinases relacionadas à Cdc2. CDK10 é essencial na fase G2/M do ciclo celular, possivelmente no progresso dessa fase, monitorando a replicação completa do DNA e permitindo que as células passem desse ponto de restrição. Essa proteína é um importante determinante de resistência à terapia endócrina para câncer de mama. Portanto, é um alvo potencial para o desenvolvimento de inibidores, uma vez que está presente em células cancerosas. O estudo da estrutura e função da CDK10 deverá ser realizado após sua clonagem, expressão e purificação. O cDNA da CDK10 foi amplificado por reação em cadeia da polimerase (PCR), e posteriormente, o produto foi aplicado em gel de agarose para análise e purificação. O vetor de clonagem recombinante foi obtido, o qual foi clonado em células competentes e sequenciado. A obtenção do plasmídeo recombinante para expressão deu-se pela inserção do DNA nos vetores de expressão pET28a(+) e pET23a(+) (Novagen). A proteína foi expressa em células competentes e analisada por eletroforese em gel de poliacrilamida. Em seguida, a proteína obtida foi purificada em coluna de afinidade por níquel e em coluna de afinidade por ATP. Com a otimização dos resultados obtidos, será possível, futuramente, caracterizar bioquimicamente a CDK10 e elucidar suas estruturas secundária e terciária. O estudo da CDK10 irá contribuir para o entendimento da sua relação estrutura-função e sua relação com oncogenes e supressores de tumor, e o estudo estrutural para o desenvolvimento de inibidores químicos de baixo peso molecular que possa inibir especificamente a CDK10. / Cyclin-dependent kinases (CDKs) comprise a family of proteins that can be subdivided into two major groups based on their functional role in cell cycle and / or transcriptional control. Over 30 human CDKs have been identifies. CDK10 is a cyclin-dependent kinase protein that belongs to the cdc2-related kinases group. CDK10 is essential in phase G2 / M of the cell cycle, possibly in the progress of this phase, monitoring the complete DNA replication and allowing the cells to pass through this restriction point. This protein is an important determinant of resistance to endocrine therapy for breast cancer. Therefore, it is a potential target for the development of inhibitors, since it is present in cancerous cells. The study of the structure and function of CDK10 must be performed after its cloning, expression and purification. cDNA of CDK10 was amplified by polymerase chain reaction (PCR) and then the product was applied into agarose gel for analysis and purification The cloning vector was obtained, which was cloned into competent cells and sequenced. The obtaining of the recombinant plasmid for expression was due to the insertion of DNA into expression vectors pET28a(+) and pET23a(+) (Novagen). The protein was expressed in competent cells and analyzed by electrophoresis on polyacrylamide gel. Then, the obtained protein was purified by nickel affinity column and ATP affinity column. With the optimization of the results obtained, it will be possible, in the future, to biochemically characterize CDK10 and elucidate its secondary and tertiary structures. The study of CDK10 will contribute to the understanding of its structure-function relationship and its relationship with oncogenes and tumor suppressors, and the structural study for the development of low molecular weight chemical inhibitors that can specifically inhibit CDK10. The structural studies will contribute to the development of chemical inhibitors of low molecular weight that may this and other CDKs.

Avaliamos neste estudo as expressões da ciclina D1 e da proteína p21, pela técnica de Imuno-histoquímica, para detectar a presença destas proteínas nos núcleos das células do câncer de mama localmente avançado, com o objetivo de correlacionar a concentração destas proteínas com aresposta preditiva ao tratamento quimioterápico neo-adjuvante, utilizandoo esquema docetaxel associado à epirrubicina. A avaliação foi feita previamente e após a realização da quimioterapia neo-adjuvante. A avaliação pré-quimioterápica teve a finalidade de estabelecer um papel preditivo quanto à resposta ao tratamento primário. A avaliação pós-quimioterápica teve a finalidade de explorar a relação entre a persistência da proteína com intervalo livre de doença e sobrevida global. Foram selecionados 72 casos de 162 tumores localmente avançados de mama atendidos no período de janeiro de 1998 a dezembro de 2005, tratados por quimioterapia primária no Ambulatório de Mastologiado Hospital das Clínicas de Ribeirão Preto. Conclusão: a ciclina D1 está relacionada com tumores menores, bem diferenciados e hormônio-sensíveis. Já a proteína p21 está relaciona a tumores pequenos, com estádios iniciais menores, de baixo grau histológico e hormônio-sensíveis. A expressão da ciclina D1 no tumor pré-tratamento quimioterápico não foi capaz de predizer resposta à quimioterapia neo-adjuvante. No entanto, a presença da ciclina D1 e no tumor residual e da p21tanto no tumor pré-tratamento quanto no tumor residual, sugerem melhora no intervalo livre de doença e na sobrevida global. / We evaluate in this study the expressions of the cyclin D1 and the protein p21, with the technique of Immunohistochemistry, todetect the presence of these proteins in the cells of the local advanced breast cancer. The objective was correlate the concentration of these proteins with predictive response to the neo-adjuvant chemotherapy, using docetaxel associated with epirrubicina. The evaluation was performed before and after the neo-adjuvant chemotherapy. The evaluation before the neo-adjuvant treatment had the purpose to establish a predictive value of these proteins with primary treatment response. The evaluations after neo-adjuvant treatment had the purpose to explore the relation between the persistence of these proteins with disease-free survival and overall survival. We selected 72 of 162 cases of local advanced breast cancer who had treated for primary chemotherapy in Hospital das Clínicas de Ribeirão Preto in the period of January of 1998 to December of 2005. Conclusion: Our study concluded that the cyclin D1 is related with small tumors and well differentiated and hormone-sensitive tumors. The protein p21 is relates with small tumors, initial stage tumors, low grade tumors and hormone-sensitive tumors. The expression of cyclin D1 in the tumor before the treatment failed to predict response to the neo-adjuvant chemotherapy. However, the presence of the cyclin D1 in the residual tumor andthe protein p21 before the treatment and in the residual tumors suggest improvement in the disease- free survival and overall survival.

Abstract Breast cancer is the most common cancer affecting the female population of the Western world. It is a heterogeneous disease entity that encompasses tumors with remarkably different forms of behaviour, and it is therefore vital to distinguish patients with good and poor prognoses. The classical prognostic and predictive factors for breast cancer serve as tools for clinical oncologists when planning treatment, but the growing awareness of breast cancer biology is bringing about a need for novel prognostic and predictive biomarkers. This thesis examines the prognostic significance of hypoxia response and cell cycle regulators in ductal breast cancer and in triple-negative breast cancer (negative for hormone receptors and human epidermal growth factor receptor 2), concluding that PHD2 and PHD3 are associated with a good prognosis, while the role of PHD1 is controversial, as it is associated with proliferation in ductal breast cancer but with node-negative status in triple-negative breast cancer. In our experiments HIF-1α redeemed its role as a marker of an adverse prognosis, whereas the role of HIF-2α appeared to be the opposite. Our data suggest that PHDs can have other targets than the HIF-αs, and that triple-negative breast tumors express more HIF-1α and less HIF-2α and PHD3 than those with a good prognosis. Furthermore, we identified cyclin D1 as a biomarker with independent prognostic significance in ductal breast cancer, being associated with good prognostic factors and a better outcome, whereas the opposite was seen in triple-negative breast cancer. CDK4 was associated with high proliferation in triple-negative breast cancer. In addition, high levels of p16 correlated with increased survival in breast cancer patients independently of receptor status. / Tiivistelmä Rintasyöpä on naisten yleisin syöpä läntisessä maailmassa. Rintasyöpä on heterogeeninen tautiryhmä, jossa kasvaimet vaihtelevat biologiselta käyttäytymiseltään huomattavasti. Tästä syystä on tärkeää erottaa hyvä- ja huonoennusteiset potilaat. Syöpälääkärit käyttävät klassisia ennustetekijöitä hoitopäätöksiä tehdessään, mutta lisääntynyt tieto rintasyövän biologiasta on saanut aikaan tarpeen löytää uusia ennustetekijöitä. Tässä väitöskirjatyössä tutkimme hypoksiavasteen ja solusyklin säätelijöiden ennusteellisuutta duktaalisessa rintasyövässä sekä kolmoisnegatiivisessa (ei ilmennä hormonireseptoreita eikä epidermaalikasvutekijäreseptoria) rintasyövässä. PHD2 ja PHD3:n vahva ilmentyminen liittyi parempaan ennusteeseen, mutta PHD1:n esiintymisen vaikutus oli ristiriitainen. PHD1:n ilmentyminen liittyi lisääntyneeseen solujakautumiseen duktaalisessa rintasyövässä, mutta kolmoisnegatiivisessa rintasyövässä sen esiintyminen liittyi vähentyneeseen imusolmukemetastasointiin. Tutkimuksessamme HIF-1α osoittautui huonon ennusteen merkiksi. Sitä vastoin HIF-2α:n ilmentymisen vaikutus näytti liittyvän parempaan ennusteeseen. Tuloksemme osoittavat, että PHD-entsyymeillä on mahdollisesti muitakin kohteita kuin HIF-α:t. Osoitimme myös, että HIF-1α:n ilmentyminen on yleisempää ja HIF-2α:n sekä PHD3:n ilmentyminen vähäisempää kolmoisnegatiivisessa kuin duktaalisessa rintasyövässä. Lisäksi totesimme, että sykliini D1 on itsenäinen ennustetekijä liittyen parempaan ennusteeseen duktaalisessa rintasyövässä. Huomioitavaa on kuitenkin, että kolmoisnegatiivisessa rintasyövän alaryhmässä sykliini D1:n esiintyminen oli huonon ennusteen merkki. CDK4 osoittautui voimakkaan proliferaation merkiksi kolmoisnegatiivisessa rintasyövässä. Lisäksi osoitimme, että p16:n ilmentyminen liittyy parempaan ennusteeseen sekä duktaalisessa rintasyövässä että kolmoisnegatiivisessa rintasyövässä.

A thesis on Head and neck cancer focusing on dose planning, salivary gland carcinoma and Single nucleotide polymorphism. For dose planning PET/CT (Positron emissions tomography/computed tomography) with tracer gave more precise information in comparison dose planning with CT. More primary tumours and metastases were found with the acetate tracer than with glucose tracer. Acetate PET/CT also showed larger volume of tumours attributed to lipid metabolism. In a retrospective study salivary gland cancer 5-year overall survival (OS) was 53 %. Salivary gland carcinoma consists of many histopathological groups, the two largest groups being mucoepidermoid carcinoma (MEC) and adenoid cystic carcinoma (ASCC). For ACC, having the best 5-year OS, it was 70 percent. Facial palsy, advanced stage disease, lymph node metastases worsened prognosis. ACC and polymorphous low grade carcinoma (PLGA) expressed c-myc and cyclin D1 to a larger extent than MEC. In squamous cell carcinoma of the head and neck we examined the occurrence of Single Nucleotide polymorphism, SNP. We found that the SNPs in male and female patients differed from each other. In male patients the SNPs were associated with immune response while in female patients the association was to SNPs concerning inflammation. This means that different pathways were engaged in cancer development for men and women. We also found that the SNPs in patients were different from those expressed in the healthy controls.

L'agressivité des cancers est souvent liée au pouvoir métastatique des cellules tumorales et la dissémination de ces dernières peut survenir suite à un phénomène appelé la transition épithéliomésenchymateuse. Une analyse de l'expression de la Cycline A2 conduite sur des échantillons humains de tumeurs primaires colorectales et de leurs métastases correspondantes révèle que cette protéine est moins abondante dans ces dernières. Le travail décrit dans cette thèse a permis de relier la Cycline A2 au remodelage du cytosquelette d'Actine dans les fibroblastes. Cette régulation requiert la localisation cytoplasmique de la molécule ainsi que son domaine N-terminal qui ne lie pas les CDKs. Nos expériences suggèrent que cette nouvelle activité est la conséquence d'une liaison directe entre la GTPase RhoA et la Cycline A2. La présence de cette dernière augmente l'activation de RhoA par sa GEF in vitro. L'utilisation de cellules épithéliales mammaires normales a permis l'identification d'un autre partenaire, RhoC. Dans ce contexte cellulaire, l'invalidation de la Cycline A2 diminue l'activation de RhoA et, renforce celle de RhoC ce qui conduit à une augmentation de l'invasion cellulaire en matrice de collagène. Ces cellules acquièrent aussi des propriétés mésenchymateuses caractéristiques de l'EMT, et ce phénotype est exacerbé par la présence de RasV12. Ce travail établit donc l'existence de nouvelles fonctions pour la Cycline A2 qui viennent compléter le tableau de régulation de la motilité par les protéines du cycle cellulaire et contribuent à une meilleure compréhension de son rôle dans le cancer. / Cancer aggressiveness is often associated with metastases occurrence and their dissemination can arise following an epithelial to mesenchymal transition (EMT). Cyclin A2 expression is lower in metastases relative to primary colon adenocarcinoma of matched human tumors. This manuscript describes new links between Cyclin A2 and Actin cytoskeleton remodeling in fibroblasts. This regulation requires a cytoplasmic localization of the protein and its N-terminal domain, which is unable to bind CDKs. This new Cyclin A2 activity appears to be mediated by its binding to RhoA. Accordingly, the activity of its GEF is potentiated when Cyclin A2 is present, in vitro. Furthermore, we used a normal mammary epithelial cell line and identified another Cyclin A2 partner, RhoC. Cyclin A2 depletion in this context leads to a reciprocal RhoGTPase activation where RhoA activation is impaired and that of RhoC is increased. Moreover, cell invasiveness is increased in a collagen matrix following Cyclin A2 knockdown in these cells. In addition, the epithelial cells acquire mesenchymal properties, which are exarcerbated by the expression of RasV12 and are characteristic of an EMT. Our work completes the network involving cell cycle proteins in motility. These novel functions of Cyclin A2 will hopefully help to understand the impact of its deregulation in cancer.

Chez les eucaryotes supérieurs, la progression ordonnée du cycle cellulaire est régie par une dizaine de kinases Cdk-cyclines. Les altérations génétiques ou épigénétiques impliquant des oncogènes ou des gènes codant pour des suppresseurs de tumeurs sont souvent associées à l'expression ou l'activation aberrante des Cdks, favorisant ainsi la prolifération cellulaire incontrôlée et notamment le développement de cancers. Malgré la pertinence oncogénique et thérapeutique de ces protéines, leur détection est restée jusqu'à présent limitée à des méthodes indirectes et invasives. Dans ce contexte, mes travaux de thèse ont permis de développer un biosenseur peptidique fluorescent permettant de reconnaître spécifiquement les Cdk-cyclines. Associé à une stratégie de vectorisation non invasive basée sur l'utilisation de peptides vecteurs pénétrants, le biosenseur a été délivré efficacement dans les cellules. La mise au point d'une quantification ratiométrique du signal a par ailleurs permis d'évaluer l'abondance relative des Cdk-cyclines endogènes. Deux variants plus spécifiques de certains complexes ont pu être développés. Enfin, d'autres versions du biosenseur ont quant à elles permis d'évaluer sa biodistribution in vivo et de mettre au point un essai cellulaire en vue d'un criblage de petites molécules ayant un effet sur l'abondance relative des Cdk-cyclines. / Cdk-cyclins represent key regulators of cell cycle progression among superior eukaryotes. Genetic and epigenetic alterations involving oncogenes or tumor suppressor genes are often associated with aberrant expression or activation of Cdks, leading to the sustained proliferation of cells and by the way to the development of cancers. Despite the oncogenic and therapeutic relevance of these proteins, their detection has so far remained limited to indirect and invasive methods. My Ph.D. thesis work aimed in this context at developing peptidic fluorescent biosensors that specifically recognize Cdk-cyclins. Combined to cell-penetrating peptides, the biosensor was efficiently delivered into cells. Following the development of the signal ratiometric quantification, the relative abundance of endogenous Cdk-cyclins was directly evaluated in living cells. Two other variants, that are more specific towards specific Cdk-cyclin complexes, were also designed. Finally, the development of novel versions of the biosensor allowed us to evaluate its biodistribution in vivo and to set up a cell-based assay to screen small molecules having an effect on Cdk-cyclin relative abundance.

La protéine cIAP1 (cellular Inhibitor of Apoptosis Protein-1) de la famille des IAP (Inhibitor of Apoptosis Protein) est une E3 ubiquitine ligase qui présente des propriétés oncogéniques. Notre équipe s’intéresse aux processus permettant la différenciation des monocytes en macrophages. Au cours de la différenciation de nombreux modèles cellulaires (macrophages, cellules dendritiques, cellules épithéliales du colon, cellules souches hématopoïetiques, cardiomyocytes), cIAP1 sort du noyau pour se relocaliser dans le cytoplasme. La plupart des fonctions connues de cIAP1 sont liées à sa localisation cytoplasmique où elle est un régulateur important des voies de signalisation des récepteurs du TNFα et de NF-κB. Lors de la différenciation macrophagique, nous avons montré que cIAP1, une fois dans le cytoplasme, induit la dégradation de TRAF-2, un adaptateur moléculaire impliqué dans la transduction du signal des voies des récepteurs du TNFα et de NF-κB. Cette dégradation bloque la voie canonique de NF-κB et est essentielle à la différenciation terminale des monocytes en macrophages qui nécessite une activation transitoire de cette voie de signalisation. Cependant, cIAP1 est principalement exprimée dans le noyau de différents types cellulaires ce qui n’est pas en accord avec son rôle dans la signalisation cellulaire. Mon objectif a donc consisté à identifier les fonctions nucléaires de cIAP1 dans des cellules prolifératives ou lors de la différenciation macrophagique. Mon travail de thèse a permis d’identifier un rôle de cIAP1 dans la prolifération cellulaire. cIAP1 interagit avec le facteur de transcription E2F1 et favorise son recrutement sur les promoteurs des Cycline E et A impliquées dans les transitions G1/S et G2 du cycle cellulaire, ce qui augmente l’expression des transcrits et des protéines de ces deux cibles. Il semblerait que par cette activité, cIAP1 régule la prolifération des cellules et soit important dans l’équilibre entre la prolifération et la différenciation, deux mécanismes cellulaires étroitement liés. / The inhibitor of apoptosis protein cIAP1 (cellular inhibitor of apoptosis protein-1) from the IAP family (Inhibitor of Apoptosis Protein) is an E3 ubiquitin ligase that displays oncogenic properties. Our team is interested in the mecanisms that allow macrophagic differentiation from monocytes. cIAP1 is relocalised from the nucleus to the cytoplasm during the differentiation of many kind of cellular models (macrophages, dendritic cells, colon epithelial cells, hematopoietic stem cells, cardiomyocytes). The well-known functions of cIAP1 are associated with its cytoplasmic localisation, where it regulates the TNFα receptors and NF-κB signalling pathways. During macrophage differentiation, we show that cIAP1, once it is in cytoplasm, induces TRAF-2 degradation, a molecular adaptator of the TNFα receptors family and NF-κB signalling pathways. This degradation blocks the canonical pathway of NF-κB and is essential for the terminal differentiation into macrophages that needs a transitory activation of this pathway. However, cIAP1 is mainly expressed in the nucleus on many cell types which is not in accordance with its cell signalling activity. My objective was to investigate the nuclear function of cIAP1 in proliferative cells or during macrophage differentiation. My work identifies a function of cIAP1 in proliferation regulation. cIAP1 interacts with E2F1 transcription factor and favors its recruitment on Cyclins E and A promoters, both involved in G1/S and G2 phases of the cell cycle, which leads to high level of transcript and protein expression of these two targets. It seems that cIAP1 regulates the cellular proliferation and is important for the balance between proliferation and differentiation, two mechanisms tightly connected in cells.

No description available.

No description available.